At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EMA Emera Inc.
Trading 09-29 14:59:04 EDT
47.90
+0.14
+0.29%
High47.91Low47.45Vol143.20K
Open47.49D1 Closing47.76Amplitude0.96%
Mkt Cap14.65BTradable Cap14.65BTotal Shares305.78M
T/O6.84MT/O Rate0.05%Tradable Shares305.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update
Dow Jones  ·  00:00
Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update
Fastest megawatt is the winning megawatt: Tan See Leng
Lin Daoyi  ·  09-28 05:00
Fastest megawatt is the winning megawatt: Tan See Leng
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
GlobeNewswire  ·  09-24
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
GlobeNewswire  ·  09-23
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
Top 4 S-REITs Raising DPU by 10% or More
The Smart Investor  ·  09-23
Top 4 S-REITs Raising DPU by 10% or More
Forget Banks: 3 S-REITs Surprising Unitholders with Higher DPUs
The Smart Investor  ·  09-22
Forget Banks: 3 S-REITs Surprising Unitholders with Higher DPUs
Dozens of Patients Take Legal Action Against Maker of Semaglutide
Deep News  ·  09-20
Dozens of Patients Take Legal Action Against Maker of Semaglutide
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
GlobeNewswire  ·  09-18
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances
TIPRANKS  ·  09-16
Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances
MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD
TIPRANKS  ·  09-15
MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
GlobeNewswire  ·  09-09
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Dow Jones  ·  09-08
Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Emera (EMA) Gets a Hold from J.P. Morgan
TIPRANKS  ·  09-02
Emera (EMA) Gets a Hold from J.P. Morgan
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
GlobeNewswire  ·  08-30
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
Japan Breakthrough Hands Shiba Inu (SHIB) Big Win in August, but September Threat Looms
utoday  ·  08-27
Japan Breakthrough Hands Shiba Inu (SHIB) Big Win in August, but September Threat Looms
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
GlobeNewswire  ·  08-27
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
GlobeNewswire  ·  08-24
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
GlobeNewswire  ·  08-24
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Analysts Offer Insights on Utilities Companies: Emera (EMA) and Duke Energy (DUK)
TIPRANKS  ·  08-21
Analysts Offer Insights on Utilities Companies: Emera (EMA) and Duke Energy (DUK)
Zcash (ZEC) Breaks Out Unexpectedly as Key Golden EMA Cross Occurs
utoday  ·  08-18
Zcash (ZEC) Breaks Out Unexpectedly as Key Golden EMA Cross Occurs

Introduction

Company Name.
Emera Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Emera Incorporated, through its subsidiaries, engages in the generation, transmission, and distribution of electricity to various customers. The company operates through Florida Electric Utility, Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and Infrastructure, and Other segments. It generates electricity through natural gas, solar, hydroelectricity, coal, and biomass power plants. The company is also involved in the purchase, transmission, distribution, and sale of natural gas; and the provision of energy marketing, trading, and other energy asset management services. In addition, it transports re-gasified liquefied natural gas from Saint John, New Brunswick to consumers in the northeastern United States through its 145-kilometer pipeline. As of December 31, 2023, the company's electric utilities served approximately 840,000 customers in West Central Florida; 549,000 customers in Nova Scotia; 134,000 customers in the island of Barbados; 19,000 customers in the Grand Bahama Island; and gas utilities and infrastructure served approximately 490,000 customers across Florida and 540,000 customers in New Mexico. The company was incorporated in 1998 and is headquartered in Halifax, Canada.
Issue price:
--